ArticleBJU international2026
Non-surgical management vs active treatment in T1a renal cell carcinoma: a population-based study.
Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare overall and cancer-specific survival for clinical (c)T1aN0M0 renal cell carcinoma (RCC) in patients treated with non-surgical management (NSM: surveillance and watchful waiting) or active treatment (surgery and ablative treatments). PATIENTS AND
methodsIn this nationwide real-world population-based cohort study, data on clinical, demographic, and socioeconomic factors as well as tumour characteristics and cause of death were retrieved from the Renal Cell Carcinoma Database Sweden (RCCBaSe) for 3989 patients diagnosed with cT1aN0M0 RCC, 2011-2020 and treated with either NSM or active treatment. Differences in survival between NSM and active treated patients were analysed using standard and competing-risks Cox regression models.
resultsIn total, 3727 (93.4%) patients underwent active treatments, while 262 patients (6.6%) were treated with NSM. Patients in the NSM group were significantly older and had a higher comorbidity burden. During a median follow-up time of 4.1 years, all-cause mortality was significantly higher among the NSM (38.9%) than the actively treated (10.9%) patients (P < 0.001), as was cancer-specific mortality (13.0% vs 3.4%, P < 0.001). Larger tumours, older age, male sex, increased comorbidity, being unmarried or widowed, having lower disposable income, and having clear cell or papillary RCC compared with chromophobe RCC were all independently associated with poorer overall and cancer-specific survival. One of the limitations is that treatment allocation was not randomised.
conclusionNon-surgical management of cT1aN0M0 RCC was associated with poorer survival compared with surgery/ablation and should be offered mainly for patients with limited life expectancy and indolent renal tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.